August saw a steep rise in Special Access Scheme Category B medicinal cannabis approvals, beating July’s figure by almost 4,000.
The TGA rubber stamped 15,371 applications during the month, up from 11,563 (adjusted) in July – itself a record for the year to date.
Victoria-based prescribers once again led the charge with 8,091 approvals, followed by Queensland (4,231) and New South Wales (2,202).
For the second consecutive month, the state’s prescribers were responsible for more than half of SAS-B approvals in the country.
And the regulator’s year-to-date figures show 37,124 approvals originating in Victoria compared to 32,503 from the sunshine state.
Flower took a bite out of oil’s market share during the month, accounting for 41% of approvals (6,244) compared to 37% in July. Oil slipped back from 51% last month to 48% in August with 7,412 approvals.
They were followed by inhalation at 7% (1,099 approvals) and capsules at 2% (270), both unchanged from July.
Year-to-date figures show oil still leading the market over flower by 51% to 37%.
Major indications were also consistent with previous months with chronic pain accounting for 41%, anxiety 31%, sleep disorder 9%, depression 4% and PTSD 4%.